



Multicell Conjugates For Activating Antigen-Specific T Cell Responses

[View U.S. Patent Application Publication No. US-2022-0106565 in PDF format.](#)

WARF: P200046US02

Inventors: Jenny Gumperz, Dana Baiu

The Invention

The present invention from UW Madison researchers provides in vitro derived a multicell conjugate comprising an iNKT cell and a dendritic cell (DC). The invention also provides methods of making the multicell conjugate and methods of using the multicell conjugate and compositions comprising the same to treat one or more conditions associated with an antigen or methods of activating an immune response.

Stage of Development

The development of this technology was supported by WARF Accelerator. WARF Accelerator selects WARF's most commercially promising technologies and provides expert assistance and funding to enable achievement of commercially significant milestones. WARF believes that these technologies are especially attractive opportunities for licensing.

Additional Information

For More Information About the Inventors

- [Jenny Gumperz](#)

Tech Fields

- [Therapeutics & Vaccines : Oncology](#)

For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857